ArticleChemistry & biodiversity2026
Design, Synthesis, and Anti-Inflammatory Activity of Functionalized 1,2,4,5-Tetrasubstituted-Pyrimidinone.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A highly efficient aza-Michael addition reaction of 5-amino pyrimidinones with α, β-unsaturated olefins under optimized reaction conditions is reported. The resulting functionalized amino-pyrimidinone-based aza-Michael mono-adducts were obtained in good to excellent yields. These synthesized compounds were screened for their anti-inflammatory potential in RAW264.7 macrophages. Among the synthesized compounds, we identified two derivatives, 3d and 3f, as potent anti-inflammatory compounds. Our findings demonstrated that 3d and 3f maintained normal cell viability at the bioactive concentrations (1, 5, and 10 µM), effectively reduced the production of proinflammatory mediators such as nitric oxide and proinflammatory cytokines including interleukin-6 and tumor necrosis factor-α. In addition, immunoblotting results revealed that 3d and 3f downregulate the protein expression of i-NOS and COX-2 in LPS-activated RAW264.7 macrophages. Furthermore, molecular docking was performed to elucidate the binding mechanism of these compounds and to establish a correlation between the in vitro results and the in silico data. Collectively, our results suggest that 3d and 3f attenuated the LPS-induced inflammatory response in macrophages and can be a structural lead for the development of novel anti-inflammatory agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.